Vertex Pharmaceuticals (VRTX) Income towards Parent Company (2009 - 2026)
Vertex Pharmaceuticals (VRTX) posted quarterly Income towards Parent Company of $1.0 billion for Q1 2026, up 59.59% year-over-year from $646.3 million in Q1 2025, and down 13.41% quarter-over-quarter from $1.2 billion in Q4 2025.
Vertex Pharmaceuticals (VRTX) Income towards Parent Company (2009 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Income towards Parent Company history runs 17 years deep, the most recent figure standing at $1.0 billion for Q1 2026.
- In Q1 2026, Income towards Parent Company rose 59.59% year-over-year to $1.0 billion; the TTM figure through Mar 2026 stood at $4.3 billion (up 538.7% YoY), while the FY2025 annual figure was $4.0 billion, up 838.09% from the prior year.
- Income towards Parent Company for Q1 2026 stood at $1.0 billion, down from $1.2 billion in the prior quarter.
- The five-year high for Income towards Parent Company was $1.2 billion in Q4 2025, with the low at -$3.6 billion in Q2 2024.
- The 5-year median for Income towards Parent Company is $930.5 million (2022), against an average of $670.0 million.
- The sharpest annual moves came in 2022 and 2024: Income towards Parent Company soared 1109.7% in 2022, then slumped 492.44% in 2024.
- Vertex Pharmaceuticals' Income towards Parent Company stood at $818.9 million in 2022, then climbed by 18.31% to $968.8 million in 2023, then retreated by 5.76% to $913.0 million in 2024, then soared by 30.46% to $1.2 billion in 2025, then retreated by 13.41% to $1.0 billion in 2026.
- Business Quant data shows VRTX's Income towards Parent Company at $1.0 billion in Q1 2026, $1.2 billion in Q4 2025, and $1.1 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.10 Bn |
| Mar 31, 2026 | 1.03 Bn |
| Dec 31, 2025 | 1.19 Bn |
| Sep 30, 2025 | 1.08 Bn |
| Jun 30, 2025 | 1.03 Bn |
| Mar 31, 2025 | 646.30 Mn |
| Dec 31, 2024 | 913.00 Mn |
| Sep 30, 2024 | 1.05 Bn |
| Jun 30, 2024 | -3.59 Bn |
| Mar 31, 2024 | 1.10 Bn |
| Dec 31, 2023 | 968.80 Mn |
| Sep 30, 2023 | 1.04 Bn |
| Jun 30, 2023 | 915.70 Mn |
| Mar 31, 2023 | 699.80 Mn |
| Dec 31, 2022 | 818.90 Mn |
| Sep 30, 2022 | 930.50 Mn |
| Jun 30, 2022 | 810.50 Mn |
| Mar 31, 2022 | 762.10 Mn |
| Dec 31, 2021 | 770.10 Mn |
| Sep 30, 2021 | 851.90 Mn |